agenT 04002
Alternative Names: agenT 04002; agenT-04002-engineered T cell receptor therapy - MiNK TherapeuticsLatest Information Update: 06 Oct 2021
At a glance
- Originator AgenTus Therapeutics
- Developer MiNK Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 23 Sep 2020 agenT 04002 is available for licensing as of 23 Sep 2020. https://agentustherapeutics.com/collaborations/
- 23 Sep 2020 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral)
- 23 Sep 2020 Pharmacodynamics data from preclinical trial in acute myeloid leukemia released by AgenTus Therapeutics